GRI Bio Inc (GRI)

[zj3001]

Additional data added here…

$GRI is very transparent on their goal here. Just read between the lines, Pharma partner or Buyout incoming!

✅Company stated earlier this year that it will have a partner or implied buyout when positive Phase2 verified proof of concept.

b2idigital.com/gri-bio

✅ News last week stating positive phase 2 data has been demonstrated, study on going.

gribio.com/gri-bio-presen…

✅ Phase 2 expected to be done this year (2024).

clinicaltrials.gov/study/NCT06331…

✅ 10-Q 8/14/24, Page 9, “Based on the Company’s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2025.”

s3.amazonaws.com/sec.irpass.cc/…

✅Nasdaq compliance due by March 2025.

✅Executives have a track record of building pharma drugs/companies and selling them off. Their profiles discuss deal markers, IP protection, acquisition/mergers.

✅2.93m shares OS

✅ GRI Bio’s key executives own the following amounts of shares:

Walter Marc Hertz, CEO, holds approximately 385,510 shares.

Albert Agro, Chief Medical Officer, owns around 172,189 shares.

Vipin Chaturvedi, Chief Scientific Officer, also owns 172,189 shares.

Leanne Kelly, Chief Financial Officer, holds 83,333 shares.

Grok has this info for insiders

Based on the latest available data up to October 19, 2024, GRI Bio, Inc. (GRI) is largely owned by insiders,

- **Joseph E. Payne** owns **29.42%** of the company, making him the largest individual shareholder with 861,250 shares.
- **Arcturus Therapeutics Holdings Inc** holds **28.82%**.
- **Walter Marc Hertz** has **13.17%**.
- **Ofir Levi** owns **6.72%**.
- **Albert Agro** and **Vipin Chaturvedi** each own **5.88%**.
- **Richard Ammer** and **Pharma Gmbh Salmon** each hold **1.61%**.